Drug profile · INN
pegfilgrastim
PELGRAZ
pegfilgrastim (PELGRAZ) is a granulocyte colony stimulating factor receptor agonist. Associated with Accord Healthcare Pty.. Current US regulatory status: approved.
Drug details — pegfilgrastim
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 19
- Data quality
- 0.83
Quick answer
pegfilgrastim (PELGRAZ) is a granulocyte colony stimulating factor receptor agonist. Associated with Accord Healthcare Pty.. Current US regulatory status: approved.
Key facts
Mechanism of action
Granulocyte colony stimulating factor receptor agonist
Primary target: Granulocyte colony-stimulating factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pegfilgrastim?
pegfilgrastim (PELGRAZ) is a granulocyte colony stimulating factor receptor agonist. Associated with Accord Healthcare Pty.. Current US regulatory status: approved.
What is the brand name for pegfilgrastim?
PELGRAZ is a marketed brand name for pegfilgrastim. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegfilgrastim?
pegfilgrastim has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.